Efficacy of ulipristal acetate (UPA) for the treatment of expulsion uterine myomas: report of two cases.

Publisher: Informa Healthcare Country of Publication: England NLM ID: 8807913 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-0766 (Electronic) Linking ISSN: 09513590 NLM ISO Abbreviation: Gynecol Endocrinol Subsets: MEDLINE

Publication: London : Informa Healthcare
Original Publication: [Carnforth, Lancashire ; Park Ridge, N.J.] : Parthenon Pub., [c1987-

Leiomyoma/*drug therapy ; Norpregnadienes/*therapeutic use ; Uterine Hemorrhage/*drug therapy ; Uterine Neoplasms/*drug therapy; Blood Transfusion ; Emergencies ; Female ; Humans ; Leiomyoma/complications ; Leiomyoma/pathology ; Leiomyoma/therapy ; Middle Aged ; Rupture, Spontaneous/complications ; Rupture, Spontaneous/drug therapy ; Rupture, Spontaneous/therapy ; Uterine Hemorrhage/etiology ; Uterine Hemorrhage/therapy ; Uterine Neoplasms/complications ; Uterine Neoplasms/pathology ; Uterine Neoplasms/therapy

Expulsion leiomyoma can represent an emergency condition and may lead to severe vaginal hemorrhage with anemia and urgent hysterectomy. Among medical treatments used for leiomyoma, Selective progesterone receptor modulators (SPRM) and, in particular, Ulipristal Acetate (UPA) have been proved to be effective in the management of bleeding and myoma size reduction. However, to our knowledge, there are no cases reported in literature on the use of UPA used as 'emergency' medical therapy in patients with severe anemia and vaginal bleeding due to expulsion leiomyoma. In this paper we would report two cases of patients affected by expulsion myoma successfully treated with UPA with immediate resolution of vaginal bleeding and subsequent elective conservative treatment.

Keywords: Ulipristal acetate; anemization; emergency; hemorrhage; leiomyoma

0 (Norpregnadienes)
YF7V70N02B (ulipristal acetate)

Date Created: 20191228 Date Completed: 20210401 Latest Revision: 20210401

20250114

10.1080/09513590.2019.1707795

31878806